Alexander A. Cohen

Alexander A. Cohen

Auto-generated profile, based on publicly available information

Alexander A. Cohen

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Science
Verified
Journal Article
Open access
PDF file
ACAlexander A. Cohen
Alexander A. Cohen
PGPriyanthi N. P. Gnanapragasam
Priyanthi N. P. Gnanapragasam
YLYu E. Lee
Yu E. Lee
PHPauline R. Hoffman
Pauline R. Hoffman
SOSusan Ou
Susan Ou
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
Fighting zoonotic coronaviruses: In the past 20 years, three betacoronaviruses thought to have originated in bats have caused devastating disease in humans. The global pandemic caused by the latest such virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlights the need to protect against other strains that could present a threat to humans. Cohen et al. constructed nanoparticles displaying the protein domain that binds the host cell receptor (receptor-binding domain or RBD), either a homotypic SARS-CoV-2 particle or mosaic particles displaying RBDs from four or eight different betacoronaviruses. In mice, antibodies to the SARS-CoV-2 RBD were elicited just as well by mosaic particles as by homotypic nanoparticles. The mosaic nanoparticles elicited antibodies that, beyond recognizing the strains displayed, also recognized mismatched strains. Science , this issue p. 735

5 August 2022 in Science
Verified
Journal Article
Open access
ACAlexander A. Cohen
Alexander A. Cohen
NDNeeltje van Doremalen
Neeltje van Doremalen
AGAllison J. Greaney
Allison J. Greaney
HEHanne Andersen Andersen Elyard
Hanne Andersen Andersen Elyard
ASAnkur Sharma
Ankur Sharma
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, we designed mosaic nanoparticles that present randomly arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against epitopes that are conserved and relatively occluded rather than variable, immunodominant, and exposed. We compared immune responses elicited by mosaic-8 (SARS-CoV-2 and seven animal sarbecoviruses) and homotypic (only SARS-CoV-2) RBD nanoparticles in mice and macaques and observed stronger responses elicited by mosaic-8 to mismatched (not on nanoparticles) strains, including SARS-CoV and animal sarbecoviruses. Mosaic-8 immunization showed equivalent neutralization of SARS-CoV-2 variants, including Omicrons, and protected from SARS-CoV-2 and SARS-CoV challenges, whereas homotypic SARS-CoV-2 immunization protected only from SARS-CoV-2 challenge. Epitope mapping demonstrated increased targeting of conserved epitopes after mosaic-8 immunization. Together, these results suggest that mosaic-8 RBD nanoparticles could protect against SARS-CoV-2 variants and future sarbecovirus spillovers.

1 September 2021 in Cell Reports
Verified
Journal Article
Open access
CJClaudia A. Jette
Claudia A. Jette
ACAlexander A. Cohen
Alexander A. Cohen
PGPriyanthi N.P. Gnanapragasam
Priyanthi N.P. Gnanapragasam
FMFrauke Mücksch
Frauke Mücksch
YLYu E. Lee
Yu E. Lee
CBChristopher O. Barnes
Christopher O. Barnes
Many anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) neutralizing antibodies target the angiotensin-converting enzyme 2 (ACE2) binding site on viral spike receptor-binding domains (RBDs). Potent antibodies recognize exposed variable epitopes, often rendering them ineffective against other sarbecoviruses and SARS-CoV-2 variants. Class 4 anti-RBD antibodies against a less-exposed, but more-conserved, cryptic epitope could recognize newly emergent zoonotic sarbecoviruses and variants, but they usually show only weak neutralization potencies. Here, we characterize two class 4 anti-RBD antibodies derived from coronavirus disease 2019 (COVID-19) donors that exhibit breadth and potent neutralization of zoonotic coronaviruses and SARS-CoV-2 variants. C118-RBD and C022-RBD structures reveal orientations that extend from the cryptic epitope to occlude ACE2 binding and CDRH3-RBD main-chain H-bond interactions that extend an RBD β sheet, thus reducing sensitivity to RBD side-chain changes. A C118-spike trimer structure reveals rotated RBDs that allow access to the cryptic epitope and the potential for intra-spike crosslinking to increase avidity. These studies facilitate vaccine design and illustrate potential advantages of class 4 RBD-binding antibody therapeutics.

7 April 2023 in Science
Verified
Journal Article
Open access
ESEllen L. Shrock
Ellen L. Shrock
RTRichard T. Timms
Richard T. Timms
TKTomasz Kula
Tomasz Kula
EMElijah L. Mena
Elijah L. Mena
AWAnthony P. West
Anthony P. West
SEStephen J. Elledge
Stephen J. Elledge
Despite the vast diversity of the antibody repertoire, infected individuals often mount antibody responses to precisely the same epitopes within antigens. The immunological mechanisms underpinning this phenomenon remain unknown. By mapping 376 immunodominant “public epitopes” at high resolution and characterizing several of their cognate antibodies, we concluded that germline-encoded sequences in antibodies drive recurrent recognition. Systematic analysis of antibody-antigen structures uncovered 18 human and 21 partially overlapping mouse germline-encoded amino acid–binding (GRAB) motifs within heavy and light V gene segments that in case studies proved critical for public epitope recognition. GRAB motifs represent a fundamental component of the immune system’s architecture that promotes recognition of pathogens and leads to species-specific public antibody responses that can exert selective pressure on pathogens.

6 May 2024 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
RHRory A. Hills
Rory A. Hills
TTTiong Kit Tan
Tiong Kit Tan
ACAlexander A. Cohen
Alexander A. Cohen
JKJennifer R. Keeffe
Jennifer R. Keeffe
AKAnthony H. Keeble
Anthony H. Keeble
MHMark R. Howarth
Mark R. Howarth
Defending against future pandemics requires vaccine platforms that protect across a range of related pathogens. Nanoscale patterning can be used to address this issue. Here, we produce quartets of linked receptor-binding domains (RBDs) from a panel of SARS-like betacoronaviruses, coupled to a computationally designed nanocage through SpyTag/SpyCatcher links. These Quartet Nanocages, possessing a branched morphology, induce a high level of neutralizing antibodies against several different coronaviruses, including against viruses not represented in the vaccine. Equivalent antibody responses are raised to RBDs close to the nanocage or at the tips of the nanoparticle’s branches. In animals primed with SARS-CoV-2 Spike, boost immunizations with Quartet Nanocages increase the strength and breadth of an otherwise narrow immune response. A Quartet Nanocage including the Omicron XBB.1.5 ‘Kraken’ RBD induced antibodies with binding to a broad range of sarbecoviruses, as well as neutralizing activity against this variant of concern. Quartet nanocages are a nanomedicine approach with potential to confer heterotypic protection against emergent zoonotic pathogens and facilitate proactive pandemic protection.

26 April 2021 in bioRxiv
Verified
Preprint
Open access
CJClaudia A Jette
Claudia A Jette
ACAlexander A. Cohen
Alexander A. Cohen
PGPriyanthi N.P. Gnanapragasam
Priyanthi N.P. Gnanapragasam
FMFrauke Muecksch
Frauke Muecksch
YLYu E. Lee
Yu E. Lee
CBChristopher O. Barnes
Christopher O. Barnes
Summary: Many anti-SARS-CoV-2 neutralizing antibodies target the ACE2-binding site on viral spike receptor-binding domains (RBDs). The most potent antibodies recognize exposed variable epitopes, often rendering them ineffective against other sarbecoviruses and SARS-CoV-2 variants. Class 4 anti-RBD antibodies against a less-exposed, but more-conserved, cryptic epitope could recognize newly-emergent zoonotic sarbecoviruses and variants, but usually show only weak neutralization potencies. We characterized two class 4 anti-RBD antibodies derived from COVID-19 donors that exhibited broad recognition and potent neutralization of zoonotic coronavirus and SARS-CoV-2 variants. C118-RBD and C022-RBD structures revealed CDRH3 mainchain H-bond interactions that extended an RBD β-sheet, thus reducing sensitivity to RBD sidechain changes, and epitopes that extended from the cryptic epitope to occlude ACE2 binding. A C118-spike trimer structure revealed rotated RBDs to allow cryptic epitope access and the potential for intra-spike crosslinking to increase avidity. These studies facilitate vaccine design and illustrate potential advantages of class 4 RBD-binding antibody therapeutics.